Paper Details

  1. Home
  2. Paper Details

Daclatasvir/asunaprevir based direct-acting antiviral therapy ameliorate hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis: a case report.

Author: EndoTetsu, MurakamiReiichi, NakamuraMasayuki, NakamuraNorio, NaritaIkuyo, ShimadaMichiko, TomitaHirofumi, YamabeHideaki

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This case report describes a patient with HCV-associated cryoglobulinemic membranoproliferative glomerulonephritis (MPGN) with renal dysfunction who was treated with daclatasvir/asunaprevir (DCV/ASV). The report found that DCV/ASV treatment cleared HCV RNA and improved renal function without significant side effects.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Direct-acting antivirals (DAAs) dramatically improve the treatment of hepatitis C virus (HCV) infections. However, the effects of DAAs on extra-hepatic manifestations such as HCV-associated glomerulonephritis, especially in cases with renal dysfunction, are not well elucidated. CASE PRE...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372252/

データ提供：米国国立医学図書館（NLM）

New Hope for Hepatitis C: Direct-Acting Antivirals Show Promise in Treating Glomerulonephritis

Hepatitis C virus (HCV) can cause a variety of complications, including glomerulonephritis, a kidney disease. This case report describes a patient with HCV-associated cryoglobulinemic membranoproliferative glomerulonephritis (MPGN) who received treatment with the direct-acting antivirals (DAAs) daclatasvir/asunaprevir (DCV/ASV). The patient experienced significant improvement in their renal function and other symptoms after receiving DCV/ASV therapy. The case report suggests that DAAs may be effective in treating HCV-associated glomerulonephritis, even in cases with pre-existing renal dysfunction.

Navigating the Complexities of HCV: A Journey Towards Healing

The case report highlights the potential benefits of DAAs in treating HCV-associated glomerulonephritis. Think of it like a camel caravan encountering a hidden oasis in the desert; finding the right treatment can provide much-needed relief and hope for recovery. This case report adds to the growing body of evidence suggesting that DAAs can have a positive impact on extra-hepatic manifestations of HCV, such as kidney disease.

A Multifaceted Approach to HCV: Addressing the Whole Patient

This case report underscores the importance of a comprehensive approach to HCV treatment, addressing not only the viral infection but also its potential complications. It’s like a camel caravan preparing for a long desert journey; taking care of every detail, from supplies to health, is crucial for success. By considering the whole patient and their individual needs, healthcare professionals can provide the best possible care for those with HCV and its associated complications.

Dr. Camel's Conclusion

This case report offers a glimmer of hope for patients with HCV-associated glomerulonephritis. It’s like a camel caravan finding a hidden spring in the desert, a source of renewal and hope for a brighter future. DAAs represent a powerful new tool in the fight against HCV, potentially offering a path to healing for both the liver and the kidneys.

Date :
  1. Date Completed 2018-02-22
  2. Date Revised 2021-12-04
Further Info :

Pubmed ID

28356063

DOI: Digital Object Identifier

PMC5372252

Related Literature

Article Analysis
・Side Effects of daclatasvir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.